Sort   by:  
 Page size 
ProteomicsAn integrative proteomic approach during Alzheimer’s disease progression in Tau PS19 mice
Alzheimer's disease (AD) is a slowly progressive neurodegenerative disease associated with cognitive, functional, and behavioral impairments characterized by the progressive accumulation of extracellular amyloid-beta plaques and intracellular neurofibrillary tangles of hyperphosphorylated tau protei...
ORGANISM(S): Mus musculus (Mouse) 
2026-06-15 | PXD066515 | Pride
ProteomicsProteomic Analysis of Extracellular Vesicles Derived from Human Pluripotent Stem Cells
Extracellular vesicles (EVs) and secretory factors are key to intercellular communication, yet their molecular dynamics in human pluripotent stem cells (hPSCs) are not well understood. We identified a key EV surface protein that regulates hPSC stemness, enhances growth, and promotes EV endocytosis. ...
ORGANISM(S): Homo sapiens (Human) 
2025-02-14 | PXD056373 | Pride
Extracellular vesicles Human pluripotent stem cells 
GenomicsThese are from Korean HCC samples with exome sequencing
Hepatic resection is the most curative treatment option for early-stage hepatocellular carcinoma, but is associated with a high recurrence rate, which exceeds 50% at 5 years after surgery. Understanding the genetic basis of hepatocellular carcinoma at surgically curable stages may enable the identif...
EGAS00001000604 | EGA
UnknownMediation of Age and Thrombectomy Outcome by Neuroimaging Markers of Frailty in Patients With Stroke.

Importance

Age is a leading predictor of poor outcomes after brain injuries like stroke. The extent to which age is associated with preexisting burdens of brain changes, visible on neuroimaging but rarely considered in acute decision-making or trials, is unknown.

Objectives

To explore...
S-EPMC10762575 | biostudies-literature
UnknownAssessment of Discrepancies Between Follow-up Infarct Volume and 90-Day Outcomes Among Patients With Ischemic Stroke Who Received Endovascular Therapy.
Not available
S-EPMC8571657 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurrent ischaemic cardiovascular events with the monoclonal antibody to proprotein convertase subtilisin/kexin type 9 alirocumab, as well as lower al...
S-EPMC11249957 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.

Background

Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patie...
S-EPMC8822604 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Background

Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain.

Met...

S-EPMC9422774 | biostudies-literature
UnknownMapping the human genetic architecture of COVID-19.
The genetic make-up of an individual contributes to the susceptibility and response to viral infection. Although environmental, clinical and social factors have a role in the chance of exposure to SARS-CoV-2 and the severity of COVID-191,2, host genetics may also be important. Identifying...
S-EPMC8674144 | biostudies-literature
Sort   by:  
 Page size